OXUR Oxurion NV

Leuven, BELGIUM, Boston, MA, US – June 1, 2023 – 8.00 AM CET – Oxurion NV (Euronext Brussels: OXUR) (the "Company" or "Oxurion"), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that the company will participate in three conferences in June:

Knowledge for Growth 2023 AntwerpJune 1, 2023Flanders Meeting & Convention Center Antwerp Michael Dillen, Chief Business Officer, will be available for meetings.

BIO International 2023June 5-8, 2023Boston Convention and Exhibition Center Tom Graney, CEO, will be available for meetings.

Clinical Trials at the SummitJune 10, 2023Pendry Park City, Park City, UTTom Graney, CEO, will be available for meetings.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

For further information please contact:

Attachment

• EN

Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Oxurion NV (EU:OXUR)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025